Technologies, Articles

MMX™ technology and its applications in gastrointestinal diseases

mmx-technology

The Multimatrix™ (MMX™) preparation MMX™ is a recently obtained drug formulation

developed to facilitate release of high concentrations of active drugs into the colon, with a homogeneous distribution along all colonic segments, particularly the most distal ones; the distal colonic tracts, indeed, are the most difficult to reach in significant amounts when a drug is given orally.

The MMX™ formulation, as shown below, contains called “Lipophilic-matrix and hydrophilic-matrix” that actually surround the central nucleus, which is the active drug (mesalazine or budesonide).

MMX-Pic-1

parts of this technology:

After reaching this site, the activity of the tablet core, which consists of hydrophilic

excipients (thought to drive the tablet to swell into a viscous gel mass, slowing the release of the drug) and lipophilic excipients (thought to slow the penetration

of aqueous fluids into the tablet core), results in a homogenous and prolonged exposure

of the whole colonic mucosa to the embedded substance.

How to release:

Treatment of bowel diseases using MMX technology:

One of the potentially largest applications of this technology could be its use with antibiotics. Rifamycin SV-MMX™ has been formulated as a tablet for the treatment of colonic bacterial infections, including traveler’s diarrhea (TD), usually contracted from contaminated food and less commonly from water.

From this it can be concluded that MMX™ formulation for more effective treatment than other formulations such as I.R. or … for the treatment of intestinal diseases (especially colon) can be used in an acceptable and effective way.

Advantages of MMX™ formulation:

The advantage of the MMX formulation is not limited to this point (complete and uniform coverage of the colon) but also its use once a day (Once daily) and sometimes a daily dose (budesonide), in addition to effectively delivering the drug molecule to the site of effect. The systemic absorption of the drug (mesalazine, budesonide) is very low and this reduces the side effects of the drug compared to other formulations.

Reference:
1Nardelli, S., Pisani, L.F., Tontini, G.E., Vecchi, M. and Pastorelli, L., 2017. MMX® technology and its applications in gastrointestinal diseases. Therapeutic Advances in Gastroenterology, 10(7), pp.545-552.
-2 Maconi, G., Camatta, D., Cannatelli, R., Ferretti, F., Gabrielli, A.C. and Ardizzone, S., 2021. Budesonide MMX in the Treatment of Ulcerative Colitis: Current Perspectives on Efficacy and Safety. Therapeutics and Clinical Risk Management17, p.285.